Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Investors

Open Orphan plc has changed its name to hVIVO plc (Ticker: HVO)

Watch hVIVO’s Capital Markets Day 2022 presentation here.

hVIVO is a publicly traded company on the London AIM and Euronext Growth stock exchanges under the symbol HVO

Yamin 'Mo' Khan

CEO at hVIVO

“We are the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services. We provide end-to-end services to our diverse portfolio of clients, including four of the top 10 global biopharma companies. I look forward to driving further growth across the business this year and converting this substantial progress into value for our shareholders.”

Regulatory News

Reasons to Invest

Rapidly Growing
Specialist CRO

£0M
2021 Revenue
£0M
2021 EBITDA
£0M
Cash at year end
31 December 2021

Leader in Human
Challenge Trials

0 +
Completed Human
Challenge Studies
0 +
Challenge Study
Models
0 +
Volunteers inoculated

Operational
Excellence

0 +
Volunteers screen
2021
£5-10M
Typical study size
0%
Trial recruitment success

Well Positioned
for Growth

0 +
c.45% increased
Bed capacity
0 +
Weekly On-site
Screening Capacity
£0M
+
Contracted Order Backlog
1-June-22

Company at a Glance

Deep roots
Dating back to 1946 with the UK Common Cold Unit
30+ Years
completing human challenge studies
Working with
4/10
Top Biopharma
Companies
Industry leading safety
record across 60+ challenge trials
First global
SARS-CoV-2
Challenge trial
FluCamp
tech-enabled Generic screening Recruitment platform

Capital Markets Day – November 2022

02 Nov 2022
Capital Markets Day
Watch

Latest Presentation Deck

09 Sep 2022
H1 2022 Financial Results
Download

Latest Investor Presentation

See more
Meet our experienced executive management team
Meet the team
AIM Rule 26

Combined Services

hVIVO Capability
Venn Life Sciences Capability
CMC
Preclinical
Phase I
Challenge
Study
Lab Services
Phase II
Biometrics
Regulatory
Venn Breda
Venn Paris
Biobank
Manchester
Dublin
Plumbers Row
Whitechapel Hotel
QMB
hVIVO's Location
Venn Location

End-To-End Early Clinical Development Services

hVIVO
Venn Life Sciences
FluCamp
Syringe inserted into medicine bottle

hVIVO is the world leader in testing infectious and respiratory disease products using human challenge study models and has developed the world's first COVID-19 challenge study model.

Learn more
Two lab technicians inspecting test tubes

Venn Life Sciences is an Integrated Drug Development partner offering a unique combination of drug development consultancy, clinical trial design and execution.

Visit Venn Life
Healthcare worker speaking with a clinical trial volunteer
FluCamp logo

FluCamp welcome volunteers to take part in our clinical trials under expertly supervised conditions.

Visit FluCamp

Interested in investing in hVIVO?
Contact our Investor Relations team.

IR@hVIVO.com
chevron-downcross-circle